Researchers are reporting that a multipronged community intervention that targets low-income patients resulted in improved blood pressure control. The study, which involved about 1,400 uninsured patients in Argentina with uncontrolled blood pressure, used multiple approaches to control hypertension including home blood pressure monitoring, physician care, and weekly text-messaging to promote healthy lifestyle changes. Over the course of 18 months, the group receiving the intervention had a greater decrease in systolic and diastolic blood pressure than patients who received the usual medical care. The study, published in JAMA, is funded by NHLBI and NIGMS.
NHLBI In The News
Filter News Mentions
A NHLBI-funded study concluded that five to seven years of hormone replacement therapy does not shorten the lives of post-menopausal women due to increased risk of death from cardiovascular disease or cancer. The findings, published in the journal JAMA, come from a Women’s Health Initiative’s trial, which followed 27,000 women for 18 years.
The New York Times: Taking Hormones for Menopause Doesn’t Raise Early Death Risk
The Seattle Times: Study shows hormone pills don’t shorten older women’s lives
Huffington Post: Hormone Therapy Isn’t As Risky As Once Thought, New Study Finds
An NHLBI-funded study describes that how the concentration of mucins, the proteins that thicken mucus, is high in chronic bronchitis and directly associated with the severity of the condition. The findings, published in The New England Journal of Medicine, are “an important step forward for COPD research. Understanding how characteristics of mucus relate to disease severity and symptoms may help us develop new COPD therapies as well as new ways to predict who will benefit most from different treatments,” said James P. Kiley, PhD, director of the NHLBI Division of Lung Diseases.
A study published in the Annals of Internal Medicine showed that, while intensive systolic blood pressure control increased the risk for chronic kidney disease events, it was outweighed by the potential cardiovascular benefits. The study is a subgroup analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
In a large analysis of genetic data, a team of researchers partly funded by NHLBI found that heart disease and Type 2 diabetes, the two diseases that are the leading cause of global morbidity and mortality, are linked by the same genes. The study published in Nature Genetics offers potential for drugs that could address both conditions.
Business Standard: One pill to ward off diabetes, heart disease could soon be reality
Medical News Today: Type 2 diabetes shares risk genes with heart disease
Researchers partly funded by NHLBI have used a modified version of CRISPR, the gene editing technique, to identify genetic regulatory elements (enhancers) involved in autoimmune diseases. According to the researchers, the findings, published in Nature, start to “unlock the fundamental circuitry of immune cell regulation, which will dramatically increase our understanding of disease.”
Anti-inflammatory drugs could cut the risk of heart attacks and strokes, according to a study published on The New England Journal of Medicine. The researchers reported a 15-percent reduction in risk of a cardiovascular event, including fatal and non-fatal heart attacks and strokes, for clinical trial participants who received 150 or 300 mg of an anti-inflammatory drug, compared with those on the placebo.
NHLBI-funded studies published by The New England Journal of Medicine provide additional support for intensive blood pressure control in patients with high risk of cardiovascular disease. The study about the cost-effectiveness of this approach “is important not just because it shows that the long-term benefits of intensive blood pressure treatment outweigh considerations about costs and side effects, but because of its population-wide implications,” said co-author Lawrence Fine M.D., Dr.P.H., Chief of the Branch of Clinical Applications and Prevention at NHLBI. The authors of the study on patient-reported outcomes found that intensive blood pressure treatment appeared to be safe and well tolerated.
The New England Journal of Medicine: Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
The New England Journal of Medicine: Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes
DoctorsLounge: Intensive BP Treatment Appears Safe, Well Tolerated
MedpageToday: SPRINT's Intense BP Targeting Likely Cost-Effective
A medical strategy involving the use of natriuretic peptide as a biomarker does not appear to benefit patients with heart failure, according to researchers. Their study, called GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT), compared the biomarker-guided strategy to usual care among a group of high-risk heart failure patients and found no difference between the two approaches in terms of hospitalization and heart-related death. Although the GUIDE-IT study itself was halted in 2016 because it showed no benefit, the researchers have now published the details of their study in the Journal of the American Medical Association. NHLBI funded the study.
Duke Clinical Research Institute: Biomarker-guided therapy in heart failure does not add to usual care, say researchers
MedPage Today: NT-proBNP Tx Disappoints for HF Drug Titration
Medical Xpress: NT-ProBNP-guided treatment no benefit in high-risk HFrEF
There has been a substantial reduction in racial differences in survival after in-hospital cardiac arrest, with a greater improvement in survival among black patients compared with white patients, according to a study published by JAMA Cardiology.
Lincoln Journal Star: Racial Gap Narrows for Survival of Hospitalized Cardiac Arrest Patients
Physician's Briefing: Smaller Racial Gap in Survival After In-Hospital Cardiac Arrest
MedPage Today: Racial Gap Closes for In-Hospital Cardiac Arrest Survival